Stockreport

Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc.  (ELTX) 
PDF Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) [Read more]